Press Releases

Press Releases

January 22, 2020
Favorable safety and tolerability were demonstrated in hypertriglyceridemia patients in the study Primary and key secondary endpoints were met with significant reduction in apoC-III and triglyceride levels More than 90% of patients achieved serum triglycerides ≤ 150 mg/dL at the highest monthly
January 10, 2020
BOSTON and CARLSBAD, Calif. , Jan. 10, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today the initiation of the CARDIO-TTRansform Phase 3 cardiovascular
January 2, 2020
Patients treated with AKCEA-APO(a)-L Rx received pre-specified endpoints for Lp(a) levels with favorable safety and tolerability profile Global Lp(a)HORIZON Phase 3 cardiovascular outcomes study underway BOSTON and CARLSBAD, Calif. , Jan. 02, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc.
December 18, 2019
Data from Phase 2 clinical trial of AKCEA-APOCIII-LRx anticipated in early 2020 BOSTON and CARLSBAD, Calif. , Dec. 18, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc.
December 16, 2019
Lynne Parshall appointed chair and Barbara Yanni joins as new member of the Akcea board BOSTON , Dec. 16, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. , today announced the appointments of Lynne Parshall , J.D., as chair
December 4, 2019
Alex Howarth joins Akcea from Lycera, bringing more than 25 years of experience in the biopharmaceutical sector BOSTON, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc.
November 25, 2019
BOSTON and CARLSBAD, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced initiation of the NEURO-TTRansform Phase 3 clinical trial for
November 19, 2019
BOSTON and CARSLBAD, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced the closing of the exclusive licensing agreement with Pfizer Inc.
November 13, 2019
BOSTON , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced that management will present a company
November 5, 2019
Reported Third Quarter 2019 Global Net Product Revenues of $12 Million WAYLIVRA ® (volanesorsen) launched in the E.U. Entered into a worldwide licensing agreement with Pfizer, Inc. for AKCEA-ANGPTL3-L Rx Conference Call Webcast Tuesday, November 5 , 4:30 p.m. ET at  www.akceatx.com BOSTON , Nov.